Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register
Annals of Rheumatic Diseases, 03/22/2011
Verstappen SMM et al.
– No firm conclusions can be drawn about the safety of anti-TNF during pregnancy and, without further evidence, guidelines which suggest these drugs should be avoided at the time of conception cannot yet be changed.
Patients categorised according to anti-TNF exposure as follows: (1) exposure to anti-TNF and to MTX and/or leflunomide (LEF) at conception (n=21 pregnancies); (2) exposure to anti-TNF at conception (n=50); (3) exposure to anti-TNF prior to conception (n=59); (4) no exposure to anti-TNF (control group; n=10)
88 live births in total of 130 pregnancies reported in patients who received anti-TNF before or during pregnancy
Rate of spontaneous abortion highest among patients exposed to anti-TNF at time of conception (with MTX/LEF 33% and without MTX/LEF 24%)
Compared with 17% spontaneous abortions in those with prior exposure to anti-TNF and 10% spontaneous abortions in control group
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.